P. Creaven

发表

Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943).

H. Hansen, S. Taylor, O. Selawry, 1974, Cancer chemotherapy reports.

The bioavailability in man of ICRF‐159 a new oral antineoplastic agent

P. Creaven, L. Allen, D. A. Alford, 1975, The Journal of pharmacy and pharmacology.

Phase I clinical trial of recombinant human tumor necrosis factor

A. Mittelman, R. Huben, H. Takita, 2004, Cancer Chemotherapy and Pharmacology.

A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patients with colorectal carcinoma

N. Petrelli, L. Blumenson, C. Frank, 2004, Investigational New Drugs.

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

H. Hansen, F. Muggia, O. Selawry, 1972, Cancer chemotherapy reports.

Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells.

R. Perez, J. Zdanowicz, L. Pendyala, 1996, Cancer letters.

Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial.

C. Porter, L. Pendyala, P. Creaven, 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Evaluation of clinical methods for assessing the surface roughness of restorations.

R. Smales, P. Creaven, 1979, The Journal of prosthetic dentistry.

Bowel rest, intravenous hydration, and continuous high‐dose infusion of octreotide acetate for the treatment of chemotherapy‐induced diarrhea in patients with colorectal carcinoma

N. Petrelli, Y. Rustum, M. Rodriguez-Bigas, 1993, Cancer.

A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer

N. Petrelli, C. Frank, N. Meropol, 1996, Cancer Chemotherapy and Pharmacology.

A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.

N. Petrelli, Y. Rustum, P. Burke, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen

N. Petrelli, C. Frank, Y. Rustum, 2004, Cancer Chemotherapy and Pharmacology.

Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.

L. Blumenson, N. Meropol, P. Creaven, 1998, American journal of clinical oncology.

5-Fluoro-2'-deoxyuridine: role of schedule in its therapeutic efficacy.

S. Cao, P. Creaven, Y. M. Rustum, 1993, Advances in experimental medicine and biology.

A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma.

N. Petrelli, N. Gebbia, A. Russo, 1991, Journal of chemotherapy.

5-Fluorouracil and folinic acid: summary of clinical experience.

P. Creaven, 1988, Advances in experimental medicine and biology.

Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer.

N. Petrelli, Y. Rustum, S. Madajewicz, 1984, Cancer research.

Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes

S. Arbuck, L. Pendyala, S. Lele, 2004, Cancer Chemotherapy and Pharmacology.

Clinical Pharmacokinetics of cis -Dichloro- trans -Dihydroxy- bis (Isopropylamine)Platinum(IV)

J. Cowens, L. Pendyala, S. Madajewicz, 1984 .

Characterization of cells obtained by mechanical and enzymatic means from human melanoma, sarcoma, and lung tumors.

W. Greco, Y. Rustum, Z. Pavelic, 1981, Cancer research.

Expression of Genes Related to Activity of Oxaliplatin and 5-Fluorouracil in Endoscopic Biopsies of Primary Esophageal Cancer in Patients Receiving Oxaliplatin, 5-Flourouracil and Radiation: Characterization and Exploratory Analysis with Survival

H. Nava, W. Greco, C. Leichman, 2006, Journal of chemotherapy.

Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line.

R. Perez, J. Zdanowicz, L. Pendyala, 1996, Oncology research.

Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.

R. Perez, L. Pendyala, R. Bernacki, 1995, Cancer letters.

Translational studies of glutathione in bladder cancer cell lines and human specimens.

J. Zdanowicz, L. Pendyala, D. Raghavan, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Intensive chemotherapy of small cell bronchogenic carcinoma.

J. Minna, O. Selawry, P. Creaven, 1977, Cancer treatment reports.

A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors

A. Hutson, M. Fakih, J. Black, 2007, Clinical Cancer Research.

Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial.

L. Pendyala, P. Creaven, 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors

M. Fakih, Y. Rustum, V. Badmaev, 2008, Cancer Chemotherapy and Pharmacology.

APhase I and Pharmacokinetic Study of Fixed-Dose Selenomethionine and Irinotecan in SolidTumors

M. Fakih, Y. Rustum, L. Pendyala, 2006 .

A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.

M. Fakih, Y. Rustum, V. Badmaev, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

The clinical development of paclitaxel and the paclitaxel/carboplatin combination.

R. Perez, G. Schwartz, N. Meropol, 1998, European journal of cancer.

Clinical development of iproplatin (CHIP).

L. Pendyala, S. Madajewicz, P. Creaven, 1986, Drugs under experimental and clinical research.

Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.

R. Perez, G. Schwartz, N. Meropol, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line

R. Perez, J. Zdanowicz, L. Pendyala, 1997, Cancer Chemotherapy and Pharmacology.

Dealkylation of alkoxybiphenyls by trout and frog liver preparations.

R. T. Williams, P. Creaven, W. Davies, 1967, Life sciences.

Intracellular glutathione and cytotoxicity of platinum complexes

R. Perez, J. Zdanowicz, L. Pendyala, 2004, Cancer Chemotherapy and Pharmacology.

Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity.

G. Schwartz, W. Bolanowska-Higdon, J. Zdanowicz, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Seizures associated with leucovorin administration in cancer patients.

N. Petrelli, S. Arbuck, N. Meropol, 1995, Journal of the National Cancer Institute.

Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans.

J. Cowens, S. Dutta, L. Pendyala, 1988, Cancer research.

The stimulation of hydroxylation by carcinogenic and non-carcinogenic compounds.

D. Parke, P. Creaven, 1966, Biochemical pharmacology.

Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors

M. Fakih, D. Trump, S. Strychor, 2005, Clinical Cancer Research.

Phase I and Pharmacokinetic Study of Weekly Docetaxel , Cisplatin , and Daily Capecitabine in Patientswith Advanced Solid Tumors

M. Fakih, D. Trump, S. Strychor, 2005 .

Effect of renal function impairment of iproplatin pharmacokinetics and relation to toxicity.

L. Pendyala, S. Madajewicz, P. Creaven, 1985, Cancer research.

Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.

M. Caligiuri, L. Blumenson, M. Giedlin, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Metastatic colorectal cancer: advances in biochemical modulation and new drug development.

N. Petrelli, N. Meropol, P. Creaven, 1995, Seminars in oncology.

Studies on the human metabolism of iproplatin

J. Cowens, L. Pendyala, B. Krishnan, 2004, Cancer Chemotherapy and Pharmacology.

Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin.

N. Petrelli, S. Arbuck, Y. Rustum, 1987, NCI monographs : a publication of the National Cancer Institute.

Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil

Y. Rustum, L. Pendyala, Patrick F. Smith, 2007, Clinical Cancer Research.

Pharmacokinetics and Pharmacodynamics of Mesna‐Mediated Plasma Cysteine Depletion

R. Perez, L. Pendyala, Patrick F. Smith, 2003, Journal of clinical pharmacology.

Chapter 4 – Principles of Chemotherapy for Genitourinary Cancer

D. Quinn, D. Raghavan, P. Creaven, 2005 .

Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma

N. Petrelli, P. Creaven, A. Mittelman, 2004, Cancer Chemotherapy and Pharmacology.

Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP).

L. Pendyala, A. Mittelman, S. Madajewicz, 1983, Cancer treatment reports.

Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors

G. Schwartz, Patrick F. Smith, N. Ramnath, 2003, Cancer Chemotherapy and Pharmacology.

Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors

N. Meropol, L. Pendyala, N. Clendeninn, 1997, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non‐Hodgkin's lymphoma

L. Ettinger, A. Freeman, P. Creaven, 1982, Cancer.

Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer.

J. Cowens, C. Karakousis, D. Brenner, 1990, Journal of biological response modifiers.

Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens.

E. Henderson, H. Preisler, Y. Rustum, 1979, Blood.

Rationale for chemotherapeutic approaches to prostate cancer

P. Creaven, 1984, The Prostate.

Metabolism of tyramine-1-14C by the rat.

P. Creaven, M. Tacker, W. McIsaac, 1970, Biochemical pharmacology.

Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas.

Y. Rustum, A. Mittelman, E. Ledesma, 1982, Cancer research.

Phase I clinical trial of isophosphamide (NSC-109724).

H. Hansen, F. Muggia, A. Mittelman, 1975, Cancer chemotherapy reports.

Colony growth in soft agar of human melanoma, sarcoma, and lung carcinoma cells disaggregated by mechanical and enzymatic methods.

Y. Rustum, Z. Pavelic, H. Slocum, 1980, Cancer research.

Symposium on the expanding role of folates and fluoropyrimidines in cancer chemotherapy.

P. Creaven, Y. M. Rustum, 1988, Journal of the National Cancer Institute.

Evaluation of a-Difluoromethylornithine as a Potential Chemopreventive Agent: Tolerance to Daily Oral Administration in Humans1

P. Creaven, J. Petrelli, N., 2005 .

Unusual central nervous system toxicity in a phase I study of N1N11diethylnorspermine in patients with advanced malignancy

R. Perez, N. Meropol, L. Pendyala, 2004, Investigational New Drugs.

Human Solid Tumors Growth of Cell Colonies in Soft Agar from Biopsies of Different Updated

N. Nowak, Y. Rustum, Z. Pavelic, 2006 .

Growth of cell colonies in soft agar from biopsies of different human solid tumors.

N. Nowak, Y. Rustum, Z. Pavelic, 1980, Cancer research.

Studies on the human pharmacokinetics of isophosphamide (NSC-109724).

P. Creaven, L. Allen, R. L. Nelson, 1976, Cancer treatment reports.

Pharmacokinetics of ifosfamide

P. Creaven, L. Allen, Patrick J. Creaven, 1975, Clinical pharmacology and therapeutics.

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days

S. Arbuck, J. Cowens, R. Huben, 2004, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.

L. Blumenson, C. Frank, Y. Rustum, 1999, Cancer investigation.

Human pharmacokinetics of 1-[2-[2-(4 pyridyl)-2-imidazolinyl-(1)]-ethyl]-3-(4-carboxyphenyl) urea (CGP 15720A)

L. Pendyala, S. Madajewicz, P. Creaven, 2004, Investigational New Drugs.

Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate

L. Pendyala, P. Creaven, C. Bertagna, 2004, Cancer Chemotherapy and Pharmacology.

Initial clinical experience with oral ftorafur and oral 6R,S leucovorin in advanced colorectal carcinoma.

V. Gorbunova, P. Creaven, N. Perevodchikova, 1993, European journal of cancer.

Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.

F. Muggia, P. Creaven, L. Allen, 1972, Cancer chemotherapy reports.

Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans.

N. Petrelli, L. Pendyala, P. Creaven, 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer

W. Greco, J. Cowens, L. Pendyala, 2004, Cancer Chemotherapy and Pharmacology.

Effect of microsomal activation on interaction between isophosphamide and DNA.

P. Creaven, L. Allen, 1972, Journal of pharmaceutical sciences.

Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma.

N. Petrelli, C. Frank, Y. Rustum, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The clinical toxicity of anticancer drugs and its prediction.

E. Mihich, P. Creaven, Creaven Pj, 1977, Seminars in oncology.

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.

P. Creaven, L. Allen, 1975, European journal of cancer.

PTG, a new antineoplastic epipodophyllotoxin

P. Creaven, L. Allen, Patrick J. Creaven, 1975, Clinical pharmacology and therapeutics.

Antibacterial properties of eight dental cements.

P. Creaven, M. Coogan, 1993, International endodontic journal.

A micro-method for the determination of acetaldehyde and ethanol in blood.

M. K. Roach, P. Creaven, 1968, Clinica chimica acta; international journal of clinical chemistry.

Carcinomas 5-Fluorouracil and Thymidine in Treatment of Colorectal Clinical Pharmacological Studies of Concurrent Infusion of Updated

Y. Rustum, A. Mittelman, E. Ledesma, 2006 .

Ethanol oxidation in the microsomal fraction of rat liver.

M. K. Roach, P. Creaven, W. N. Reese, 1969, Biochemical and biophysical research communications.

A fluorimetric study of the hydroxylation of biphenyl in vitro by liver preparations of various species.

D. Parke, R. T. Williams, P. Creaven, 1965, The Biochemical journal.

The fluorescence of some biphenyl derivatives.

R. T. Williams, P. Creaven, J. Bridges, 1965, The Biochemical journal.

New potential treatment modalities for disseminated prostatic cancer.

A. Mittelman, S. Madajewicz, P. Creaven, 1984, Urologic clinics of North America.

A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors

D. Sullivan, T. Mekhail, R. Bukowski, 2007, Clinical Cancer Research.

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.

B. Reigner, N. Meropol, D. Budman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of 1-ÃŸ-D-Arabinofuranosy Icytosine Metabolism by Thymidine in Human Acute Leukemia1

Y. Rustum, R. Zittoun, J. Zittoun, 2006 .

A combination of 5-fluorouracil and thymidine in advanced colorectal carcinoma

N. Petrelli, Y. Rustum, A. Sternberg, 2004, Cancer Chemotherapy and Pharmacology.

Phase II study of 3-deazauridine in advanced colorectal adenocarcinoma.

E. Ledesma, P. Creaven, D. Poster, 1982, American journal of clinical oncology.

Phase I trial and pharmacokinetics of a daily x 5 schedule of 3-deazauridine.

R. Priore, E. Henderson, A. Mittelman, 1982, Cancer treatment reports.

Clinical pharmacokinetics of 3-deazaguanine

L. Pendyala, L. Whitfield, P. Creaven, 2004, Cancer Chemotherapy and Pharmacology.

Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia.

Y. Rustum, R. Zittoun, J. Zittoun, 1985, Cancer research.

Phase I clinical trial and human pharmacokinetics of 2,4-diamino-5-adamantyl-6-methyl pyrimidine ethane sulfonate (DAMP-ES): a lipid-soluble antifolate

W. Greco, A. Mittelman, J. Pontes, 2004, Cancer Chemotherapy and Pharmacology.

Methotrexate plasma decay kinetics: possible alteration in patients undergoing gut sterilization.

P. Creaven, M. Cohen, L. Allen, 1976, British Journal of Cancer.

Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients

Martin H. Cohen, P. Creaven, B. Fossieck, 1976, Cancer.

Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer.

N. Meropol, L. Pendyala, L. Schacter, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

N. Petrelli, W. Greco, J. Cowens, 1993, Cancer research.

Matrix metalloproteinase inhibitors

N. Ramnath, P. Creaven, 2004, Current oncology reports.

Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST-2575, generation I).

M. Cohen, B. Mason, H. Lerner, 1981, Cancer treatment reports.

In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes.

P. Creaven, L. Allen, 1972, Cancer chemotherapy reports.

The clinical pharmacology of VM26 and VP16-213

P. Creaven, 1982, Cancer Chemotherapy and Pharmacology.

In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.

L. Pendyala, P. Creaven, 1993, Cancer research.

Studies on the pharmacokinetics and metabolism of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) in the dog.

J. Cowens, L. Pendyala, P. Creaven, 1982, Cancer treatment reports.

Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).

P. Creaven, M. Cohen, B. Fossieck, 1976, European journal of cancer.

Pharmacokinetics of divided‐dose ifosfamide

P. Creaven, R. Nelson, Larry M. Alien, 1976, Clinical pharmacology and therapeutics.

Clinical pharmacology of isophosphamide

P. Creaven, M. Cohen, L. Allen, 1974, Clinical pharmacology and therapeutics.

Alteration in tyramine metabolism by ethanol.

P. Creaven, M. Tacker, W. McIsaac, 1970, Biochemical pharmacology.

Surface roughness of two dental amalgams after various polishing techniques.

P. Creaven, J. Dennison, G. T. Charbeneau, 1980, The Journal of prosthetic dentistry.

Widespread metastases and renal failure from carcinoma of the soft palate: report of a case.

O. Selawry, P. Creaven, W. Burns, 1972, The Journal of urology.

The effect of butylated hydroxytoluene, butylated hydroxyanisole and octyl gallate upon liver weight and biphenyl 4‐hydroxylase activity in the rat

R. T. Williams, P. Creaven, W. Davies, 1966, The Journal of pharmacy and pharmacology.

Clinical Studies with Liposomal Doxorubicin

G. Browman, J. Cowens, P. Creaven, 1990 .

Toxicity and pharmacokinetics of a new antifolate, 2,4-diamino-5-adamantyl-6-methylpyrimidine, in dogs.

W. Greco, Z. Pavelic, E. Mihich, 1982, Cancer research.

Methotrexate in Liver and Bile after Intravenous Dosage in Man

P. Creaven, L. Allen, D. A. Alford, 1973, British Journal of Cancer.

Intrathecal methotrexate overdose without neurotoxicity. Case report and literature review

L. Ettinger, A. Freeman, P. Creaven, 1978, Cancer.

Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.

R. Priore, A. Mittelman, E. Ledesma, 1982, Cancer research.

A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC).

M. Fakih, D. Trump, L. Pendyala, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer.

W. Hicks, R. Perez, N. Meropol, 1995, Seminars in oncology.

Inhibition of macromolecular biosynthesis in cultured L1210 mouse leukemia cells by thalicarpine (NSC 68075).

P. Creaven, L. Allen, 1973, Cancer research.

Phase I study of thalicarpine (NAC-68075), a plant alkaloid of noval structure.

O. Selawry, P. Creaven, M. Cohen, 1975, Cancer chemotherapy reports.

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer

Y. Rustum, P. Creaven, E. Levine, 2007, Cancer Chemotherapy and Pharmacology.

Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer

R. Pazdur, Y. Rustum, N. Meropol, 2000, Cancer Chemotherapy and Pharmacology.

The interaction of the antineoplastic drug thalicarpine with aniline hydroxylase and microsomal cytochrome of rat liver.

P. Creaven, L. Allen, C. Williams, 1974, Xenobiotica; the fate of foreign compounds in biological systems.

Biological aspects of alcohol

M. K. Roach, P. Creaven, W. McIsaac, 1971 .

Pharmacokinetics and metabolismof nilutamide

L. Pendyala, P. Creaven, D. Tremblay, 1991 .

Platinum analogs as potential new drugs for bladder cancer.

P. Creaven, 1984, Urology.

Identification of aVDichloro-bis-isopropy lamine platinum ( II ) as a Major Metabolite of iproplatin in Humans 1

Lakshmi, J. Cowens, S. Dutta, 2006 .

Uptake and metabolism of iproplatin in murine L1210 cells

J. Cowens, L. Pendyala, P. Creaven, 2004, Cancer Chemotherapy and Pharmacology.

DNA binding of iproplatin and its divalent metabolitecis-dichloro-bis-isopropylamine platinum(II)

J. Cowens, L. Pendyala, P. Creaven, 2004, Cancer Chemotherapy and Pharmacology.

The effect of ethanol on the metabolism of amphetamine by the rat

P. Creaven, T. Barbee, 1969, The Journal of pharmacy and pharmacology.

Carboplatin for small cell lung cancer: progress toward greater efficacy and reduced toxicity.

R. Perez, L. Vaickus, D. Raghavan, 1994, Seminars in oncology.

Evaluation of three clinical methods for assessing amalgam and resin restorations.

R. Smales, P. Creaven, 1985, The Journal of prosthetic dentistry.

Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: cancer and leukemia group B trial 8171.

L. Norton, J. Anderson, D. Budman, 1985, Cancer treatment reports.

Antibiotics, vol. III. Mechanism of action of antimicrobial and antitumor agents

P. Creaven, 1976 .

Cytotoxic chemotherapeutic agents under development with a possible future role in prostate cancer

P. Creaven, 1984, The Prostate.

Pharmacokinetics and metabolism of nilutamide.

L. Pendyala, P. Creaven, D. Tremblay, 1991, Urology.

Commentary 3

P. Creaven, 2012 .

Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man.

M. Berman, P. R. Leme, P. Creaven, 1975, Cancer chemotherapy reports.

29 Dichlorodihydroxybisisopropylamine platinum IV a new antitumor platinum complex. Pharmacokinetics in the rat; relation to renal toxicity

Z. Pavelic, M. Pfister, E. Mihich, 1978 .

S-phase modulation by irinotecan: pilot studies in advanced solid tumors

Y. Rustum, L. Pendyala, H. Slocum, 2005, Cancer Chemotherapy and Pharmacology.

Analogs of amphetamine. 5. Studies of excretory metabolites of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats.

B. Ho, P. Creaven, W. McIsaac, 1971, Journal of medicinal chemistry.

EPEG, a new antineoplastic epipodophyllotoxin

P. Creaven, L. Allen, Patrick J. Creaven, 1975, Clinical pharmacology and therapeutics.

A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomes.

D. Parke, R. T. Williams, P. Creaven, 1965, The Biochemical journal.

Activation of the antineoplastic drug isophosphamide by rat liver microsomes

P. Creaven, L. Allen, 1972, The Journal of pharmacy and pharmacology.

The effect of carcinogenic and noncarcinogenic compounds on the O-dealkylating activity of the hepatic microsomal enzyme system of the rat.

P. Creaven, W. Davies, 1967, Biochemical pharmacology.

The induction of microsomal O-dealkylation by a combination of benzo(a)pyrene and phenobarbital.

P. Creaven, W. N. Reese, 1969, Chemico-Biological Interactions.

Preliminary observations on the metabolism of [1–14C]tyramine in man

P. Creaven, W. McIsaac, Mary K. Tacker, 1972, The Journal of pharmacy and pharmacology.

Phase I clinical trial of 1-2-[2-(4-pyridyl)-2-imidazoline-1-yl]-ethyl-3-(4-carboxy-phenyl)urea (CGP 15720A)

L. Pendyala, A. Mittelman, R. Huben, 2004, Cancer Chemotherapy and Pharmacology.

APhase I Pharmacokinetic and Pharmacodynamic Study of S-3304 , a Novel Matrix Metalloproteinase Inhibitor , in Patients with Advanced and Refractory SolidTumors

D. Sullivan, R. Bukowski, A. Chiappori, 2007 .

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

O. Selawry, A. Primack, P. Creaven, 1974, Cancer chemotherapy reports.

The effect of chloral hydrate on the metabolism of ethanol in mice

M. K. Roach, P. Creaven, P. J. CREAVEN, 1969, The Journal of pharmacy and pharmacology.

Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).

P. Creaven, Larry M. Allen, Martin H. Cohen, 1976, Cancer treatment reports.

A phase 1 trial of motexafin gadolinium and docetaxel for advanced solid tumors.

M. Egorin, G. Chatta, N. Ramnath, 2004, Journal of Clinical Oncology.

Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP).

D. Brenner, P. Creaven, D. Lalka, 1989, British journal of clinical pharmacology.

Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma.

R. Kane, P. Creaven, M. Cohen, 1975, Cancer chemotherapy reports.

High prevalence of Inoue-Melnick virus antibodies in patients with colorectal carcinoma.

N. Petrelli, M. Rodriguez-Bigas, P. Creaven, 1992, Cancer letters.

A phase I and pharmacokinetic (PK) study of high dose selenomethionine (SLM) in combination with irinotecan (IRI) in patients with advanced solid tumors

M. Fakih, Y. Rustum, V. Badmaev, 2005 .

Tumors Enzymatic Means from Human Melanoma , Sarcoma , and Lung Characterization of Cells Obtained by Mechanical and Updated Version

W. Greco, Y. Rustum, Z. Pavelic, 2006 .

Studies on the biosynthesis of 5-methoxytryptophol in the pineal.

P. Creaven, T. Otani, W. McIsaac, 1969, Biochimica et biophysica acta.

Binding of a new antitumor agent, thalicarpine, to DNA.

P. Creaven, L. Allen, 1974, Journal of pharmaceutical sciences.

Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans.

P. Creaven, L. Allen, F. Pelsor, 1978, Journal of pharmaceutical sciences.

Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study

Y. Rustum, Jihnhee Yu, R. Iyer, 2008, Anti-cancer drugs.

Effect of tranylcypromine sulphate on the metabolism of [14C]tyramine in vivo in the rat

P. Creaven, W. McIsaac, Mary K. Tacker, 1972, The Journal of pharmacy and pharmacology.